Oncology clinical pathways have helped health plans deliver quality care while keeping an eye on costs. The lack of standardization in pathways can be cumbersome on a busy oncology practice. If Medicare adopts a pathways model, it could offer a framework for broader use.
FOR IMMEDIATE RELEASE FEBRUARY 17, 2014
Are Oncology Clinical Pathways Coming to Medicare?
PLAINSBORO, N.J. — Oncology clinical pathways could get a tryout through Medicare, the nation’s largest provider of cancer care, sometime this year if federal officials accept a proposal from McKesson and the National Comprehensive Cancer Network.
Matthew Brow, Vice President for Business Development and Public Policy at McKesson, told Evidence-Based Oncology in the current issue that the Centers for Medicare and Medicaid Services (CMS) is reviewing a proposal from McKesson and NCCN to utilize their oncology clinical pathways. Brow told EBO, a news publication of The American Journal of Managed Care, that if the proposal is accepted, McKesson believes that CMS will roll it out as a pilot project in certain oncology practices and hospital settings sometime in 2014.
“We may be able to work on a framework in the first quarter, and start organizing the pilot perhaps six months later,” Brow told EBO. If the pilot is successful after 2 or 3 years, “We hope Medicare will look to roll it out more broadly.” For a copy of the story, click here.
Clinical care pathways have made headway in oncology care as a way to ensure quality and manage costs. Variation among practices has prompted payers to promote the use of pathways to standardize treatment options. But thus far, there is little standardization among pathways, which can create administrative challenges for a busy oncology practice. Thus far, however, the biggest payer of all, CMS, has not moved in this direction. Some believe that if CMS adopted a pathways model it would set the standard for all such programs.
The stakes for taxpayers if CMS adopted a pathways model are significant. In 2011, Medicare spent $34.4 billion for cancer care, which represents 10% of its total fee-for-service payments for the year. Today, most patients diagnosed with cancer received Medicare, and the share is only expected to grow.
CONTACT: Mary Caffrey (609) 716-7777 x 144
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for HHS leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More